Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis

Journal of Medicinal Chemistry

Volumn 54, Issue 11, 2011, Pages 3779-3792

  Andersson, Hanna ^a   Demaegdt, Heidi ^b   Johnsson, Anders ^a   Vauquelin, Georges ^b   Lindeberg, Gunnar ^a   Hallberg, Mathias ^a   Erdélyi, Máté ^c   Karlén, Anders ^a   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

13 AMINO 2 (4 HYDROXYBENZYL) 3,14 DIOXO 1,4 DIAZACYCLOTETRADEC 7 ENE 5 CARBOXAMIDO)METHYL) PHENYL)ACETIC ACID; 13 AMINO 2 (4 HYDROXYBENZYL) 4,14 DIOXO 1,5 DIAZACYCLOTETRADEC 9 ENE 6 CARBOXAMIDO)METHYL)PHENYL)ACETIC ACID; ALKENE; AMINO ACID; AMINOPEPTIDASE; ANGIOTENSIN II [3-8]; CARBOXYL GROUP; INSULIN DERIVATIVE; MACROCYCLIC COMPOUND; METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; METHYLATION; NONHUMAN; PROTEIN DEGRADATION; RING CLOSING METATHESIS;

ALKENES; ANGIOTENSIN II; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYSTINYL AMINOPEPTIDASE; DRUG DESIGN; DRUG STABILITY; LACTAMS; NOOTROPIC AGENTS; PHENYLACETATES; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958153974     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200036n     Document Type: Article

References (91)

1. Albiston, A. L.; Pederson, E. S.; Burns, P.; Purcell, B.; Wright, J. W.; Harding, J. W.; Mendelsohn, F. A.; Weisinger, R. S.; Chai, S. Y. Attenuation of scopolamine-induced learning deficits by LVV-hemorphin- 7 in rats in the passive avoidance and water maze paradigms. Behav. Brain Res. 2004, 154, 239-243. (Pubitemid 39070471)
2. Braszko, J. J. Dopamine D4 receptor antagonist L745,870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe6-Ang IV in rats. Eur. Neuropsychopharmacol. 2009, 19, 85-91.
3. Braszko, J. J.; Wlasienko, J.; Koziolkiewicz, W.; Janecka, A.; Wisniewski, K. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties. Brain Res. 1991, 542, 49-54.
4. Braszko, J. J.; Kupryszewski, G.; Witczuk, B.; Wisniewski, K. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 1988, 27, 777-783. (Pubitemid 19025386)
5. Golding, B. J.; Overall, A. D.; Brown, G.; Gard, P. R. Strain differences in the effects of angiotensin IV on mouse cognition. Eur. J. Pharmacol. 2010, 641, 154-159.
6. Kramar, E. A.; Armstrong, D. L.; Ikeda, S.; Wayner, M. J.; Harding, J. W.; Wright, J. W. The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res. 2001, 897, 114-121. (Pubitemid 32244358)
7. 4 receptor ligands, Nle1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004, 124, 341-349. (Pubitemid 38229654)
8. Lee, J.; Chai, S. Y.; Mendelsohn, F. A.; Morris, M. J.; Allen, A. M. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001, 40, 618-623. (Pubitemid 32209047)
9. Olson, M. L.; Cero, I. J. Intrahippocampal norleucine1-angiotensin IV mitigates scopolamine-induced spatial working memory deficits. Peptides 2010, 31, 2209-2215.
10. Olson, M. L.; Olson, E. A.; Qualls, J. H.; Stratton, J. J.; Harding, J. W.; Wright, J. W. Norleucine1-angiotensin IV alleviates mecamylamine- induced spatial memory deficits. Peptides 2004, 25, 233-241. (Pubitemid 38520053)
11. Tchekalarova, J.; Kambourova, T.; Georgiev, V. Interaction between angiotensin IV and adenosine A1 receptor related drugs in passive avoidance conditioning in rats. Behav. Brain Res. 2001, 123, 113-116. (Pubitemid 32506828)
12. Wayner, M. J.; Armstrong, D. L.; Phelix, C. F.; Wright, J. W.; Harding, J. W. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001, 22, 1403-1414. (Pubitemid 32770010)
13. 4 receptor subtype system to spatial learning. J. Neurosci. 1999, 19, 3952-3961. (Pubitemid 29222269)
14. Wright, J. W.; Clemens, J. A.; Panetta, J. A.; Smalstig, E. B.; Weatherly, L. A.; Kramar, E. A.; Pederson, E. S.; Mungall, B. H.; Harding, J. W. Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res. 1996, 717, 1-11. (Pubitemid 26155069)
15. Wright, J. W.; Krebs, L. T.; Stobb, J. W.; Harding, J. W. The angiotensin IV system: Functional implications. Front. Neuroendocrinol. 1995, 16, 23-52.
16. Wright, J. W.; Miller-Wing, A. V.; Shaffer, M. J.; Higginson, C.; Wright, D. E.; Hanesworth, J. M.; Harding, J. W. Angiotensin II(3-8) (ANG IV) hippocampal binding: Potential role in the facilitation of memory. Brain Res. Bull. 1993, 32, 497-502. (Pubitemid 23251954)
17. 4 receptor subtype in overcoming scopolamine- induced spatial memory deficits. Regul. Pept. 2001, 102, 147-156. (Pubitemid 33135576)
18. Pederson, E. S.; Harding, J. W.; Wright, J. W. Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. Regul. Pept. 1998, 74, 97-103. (Pubitemid 28288970)
19. 4 receptor system as a new target for the treatment of Alzheimer's disease. Drug Dev. Res. 2009, 70, 472-480.
20. 4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001, 276, 48623-48626.
21. 4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography. J. Chem. Neuroanat. 2000, 20, 339-348. (Pubitemid 32162891)
22. Fernando, R. N.; Larm, J.; Albiston, A. L.; Chai, S. Y. Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J. Comp. Neurol. 2005, 487, 372-390. (Pubitemid 40756877)
23. 4 receptors in the Macaca fascicularis brain. Brain Res. 1996, 712, 307-324.
24. Keller, S. R.; Scott, H. M.; Mastick, C. C.; Aebersold, R.; Lienhard, G. E. Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J. Biol. Chem. 1995, 270, 23612-23618.
25. Olsen, J.; Cowell, G. M.; Konigshofer, E.; Danielsen, E. M.; Moller, J.; Laustsen, L.; Hansen, O. C.; Welinder, K. G.; Engberg, J.; Hunziker, W.;Complete amino acid sequence of human intestinal aminopeptidase N as deduced from cloned cDNA. FEBS Lett. 1988, 238, 307-314.
26. Chai, S. Y.; Yeatman, H. R.; Parker, M. W.; Ascher, D. B.; Thompson, P. E.; Mulvey, H. T.; Albiston, A. L. Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neurosci. 2008, 9 (Suppl. 2), S14.
27. 4 receptor for cognitive disorders. Drug News Perspect. 2009, 22, 133-139.
28. 4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease. J. Renin-Angiotensin-Aldosterone Syst. 2008, 9, 226-237.
29. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 2006No. CD005593.
30. Cosman, K. M.; Boyle, L. L.; Porsteinsson, A. P. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin. Pharmacother. 2007, 8, 203-214. (Pubitemid 46206622)
31. Doraiswamy, P. M.; Xiong, G. L. Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin. Pharmacother. 2006, 7, 1-10. (Pubitemid 43056417)
32. Raina, P.; Santaguida, P.; Ismaila, A.; Patterson, C.; Cowan, D.; Levine, M.; Booker, L.; Oremus, M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann. Intern. Med. 2008, 148, 379-397. (Pubitemid 351665469)
33. 4 receptor: Analysis of position two- and three-modified angiotensin IVanalogs. Peptides 1999, 20, 915-920. (Pubitemid 29418025)
34. 4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides 1993, 14, 949-954.
35. 4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 1994, 15, 1399-1406. (Pubitemid 24381186)
36. Wright, J. W.; Harding, J. W. The brain RAS and Alzheimer's disease. Exp. Neurol. 2010, 223, 326-333.
37. McCoy, A. Pharmacokinetic Characterization of Angiotensin IV Analogs with Therapeutic Potential for Cancer and Dementia. Ph.D. Thesis, Washington State University, Washington, DC, 2010.
38. 4 in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J. Med. Chem. 2009, 52, 5612-5618.
39. Lukaszuk, A.; Demaegdt, H.; Szemenyei, E.; Toth, G.; Tymecka, D.; Misicka, A.; Karoyan, P.; Vanderheyden, P.; Vauquelin, G.; Tourwe, D. β-Homo-amino acid scan of angiotensin IV. J. Med. Chem. 2008, 51, 2291-2296.
40. Albiston, A. L.; Morton, C. J.; Ng, H. L.; Pham, V.; Yeatman, H. R.; Ye, S.; Fernando, R. N.; De Bundel, D.; Ascher, D. B.; Mendelsohn, F. A.; Parker, M. W.; Chai, S. Y. Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB J. 2008, 22, 4209-4217.
41. Albiston, A. L.; Pham, V.; Ye, S.; Ng, L.; Lew, R. A.; Thompson, P. E.; Holien, J. K.; Morton, C. J.; Parker, M. W.; Chai, S. Y. Phenylalanine- 544 plays a key role in substrate and inhibitor binding by providing a hydrophobic packing point at the active site of insulinregulated aminopeptidase. Mol. Pharmacol. 2010, 78, 600-607.
42. 2. Bioorg. Med. Chem. 2008, 16, 6924-6935.
43. 4 receptor. J. Pept. Sci. 2007, 13, 434-444. (Pubitemid 47082893)
44. 4 receptor ligands. J. Pept. Sci. 2006, 12, 705-713. (Pubitemid 44697843)
45. Andersson, H.; Demaegdt, H.; Vauquelin, G.; Lindeberg, G.; Karlen, A.; Hallberg, M.; Erdelyi, M.; Hallberg, A. Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). J. Med. Chem. 2010, 53, 8059-8071.
46. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat. Rev. Drug Discovery 2008, 7, 608-624. (Pubitemid 351927725)
47. Fu, G. C.; Grubbs, R. H. The application of catalytic ringclosing olefin metathesis to the synthesis of unsaturated oxygen heterocycles. J. Am. Chem. Soc. 1992, 114, 5426-5427.
48. Fu, G. C.; Nguyen, S. T.; Grubbs, R. H. Catalytic ring-closing metathesis of functionalized dienes by a ruthenium carbene complex. J. Am. Chem. Soc. 1993, 115, 9856-9857.
49. Jiang, S.; Li, Z.; Ding, K.; Roller, P. P. Recent progress of synthetic studies to peptide and peptidomimetic cyclization. Curr. Org. Chem. 2008, 12, 1502-1542.
50. Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. Application of ringclosing metathesis to the synthesis of rigidified amino acids and peptides. J. Am. Chem. Soc. 1996, 118, 9606-9614. (Pubitemid 26358319)
51. Miller, S. J.; Grubbs, R. H. Synthesis of conformationally restricted amino acids and peptides employing olefin metathesis. J. Am. Chem. Soc. 1995, 117, 5855-5856.
52. Berezowska, I.; Chung, N. N.; Lemieux, C.; Wilkes, B. C.; Schiller, P. W. Cyclic dermorphin tetrapeptide analogues obtained via ring-closing metathesis. Acta Biochim. Pol. 2006, 53, 73-76.
53. 2 retain high opioid activity. J. Med. Chem. 2007, 50, 1414-1417. (Pubitemid 46496338)
54. D'Addona, D.; Carotenuto, A.; Novellino, E.; Piccand, V.; Reubi, J. C.; Di Cianni, A.; Gori, F.; Papini, A. M.; Ginanneschi, M. Novel sst5-selective somatostatin dicarba-analogues: Synthesis and conformation -affinity relationships. J. Med. Chem. 2008, 51, 512-520. (Pubitemid 351252279)
55. Fang, W. J.; Cui, Y.; Murray, T. F.; Aldrich, J. V. Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis. J. Med. Chem. 2009, 52, 5619-5625.
56. Stymiest, J. L.; Mitchell, B. F.; Wong, S.; Vederas, J. C. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J. Org. Chem. 2005, 70, 7799-7809. (Pubitemid 41377484)
57. Carpino, L. A.; Han, G. Y. 9-Fluorenylmethoxycarbonyl aminoprotecting group. J. Org. Chem. 1972, 37, 3404-3409.
58. Chapman, R. N.; Arora, P. S. Optimized synthesis of hydrogenbond surrogate helices: Surprising effects of microwave heating on the activity of Grubbs catalysts. Org. Lett. 2006, 8, 5825-5828.
59. Stability of Polymer-Supports to Microwave Heating; Novabiochem Innovations 4/03; EMD Biosciences Inc.: La Jolla, CA.
60. Ahn, Y. M.; Yang, K.; Georg, G. I. A convenient method for the efficient removal of ruthenium byproducts generated during olefin metathesis reactions. Org. Lett. 2001, 3, 1411-1413. (Pubitemid 33629478)
61. Stymiest, J. L.; Mitchell, B. F.; Wong, S.; Vederas, J. C. Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org. Lett. 2003, 5, 47-49. (Pubitemid 37140519)
62. Hong, S. H.; Sanders, D. P.; Lee, C.W.; Grubbs, R. H. Prevention of undesirable isomerization during olefin metathesis. J. Am. Chem. Soc. 2005, 127, 17160-17161. (Pubitemid 41791016)
63. Kay, C.; Lorthioir, O. E.; Parr, N. J.; Congreve, M.; McKeown, S. C.; Scicinski, J. J.; Ley, S. V. Solid-phase reaction monitoring- chemical derivatization and off-bead analysis. Biotechnol. Bioeng. 2000, 71, 110-118. (Pubitemid 32332530)
64. Vojkovsky, T. Detection of secondary amines on solid phase. Pept. Res. 1995, 8, 236-237.
65. Tang, Z. L.; Pelletier, J. C. Preparation of amides from acids and resin bound azides: Suppression of intramolecular lactam formation. Tetrahedron Lett. 1998, 39, 4773-4776. (Pubitemid 28267307)
66. Brandt, M.; Gammeltoft, S.; Jensen, K. Microwave heating for solid-phase peptide synthesis: General evaluation and application to 15-mer phosphopeptides. Int. J. Pept. Res. Ther. 2006, 12, 349-357. (Pubitemid 44775474)
67. V-azquez, J.; Albericio, F. A useful and sensitive color test to monitor aldehydes on solid-phase. Tetrahedron Lett. 2001, 42, 6691-6693. (Pubitemid 32786749)
68. Sheppeck, J. E.; Kar, H.; Hong, H. A convenient and scaleable procedure for removing the Fmoc group in solution. Tetrahedron Lett. 2000, 41, 5329-5333. (Pubitemid 30450788)
69. Griesinger, C.; Sørensen, O. W.; Ernst, R. R. Practical aspects of the E.COSY technique. Measurement of scalar spin-spin coupling constants in peptides. J. Magn. Reson. 1987, 75, 474-492.
70. Kumar, A.; Ernst, R. R.; Wüthrich, K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem. Biophys. Res. Commun. 1980, 95, 1-6.
71. Mueller, L. P.E.COSY, a simple alternative to E.COSY. J. Magn. Reson. 1987, 72, 191-196.
72. Demaegdt, H.; Laeremans, H.; De Backer, J.-P.; Mosselmans, S.; Le, M. T.; Kersemans, V.; Michotte, Y.; Vauquelin, G.; Vanderheyden, P. M. L. Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators. Biochem. Pharmacol. 2004, 68, 893-900. (Pubitemid 39044517)
73. 4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]angiotensin IV only binds to the cystinyl aminopeptidase apoenzyme. Eur. J. Pharmacol. 2006, 546, 19-27. (Pubitemid 44331842)
74. Laeremans, H.; Demaegdt, H.; De Backer, J. P.; Le, M. T.; Kersemans, V.; Michotte, Y.; Vauquelin, G.; Vanderheyden, P. M. Metal ion modulation of cystinyl aminopeptidase. Biochem. J. 2005, 390, 351-357. (Pubitemid 41192262)
75. Vanderheyden, P. M.; Demaegdt, H.; Swales, J.; Lenaerts, P. J.; De Backer, J. P.; Vogel, L. K.; Vauquelin, G. Synergistic inhibition of the enzymatic activity of aminopeptidase N by divalent metal ion chelators. Fundam. Clin. Pharmacol. 2006, 20, 613-619. (Pubitemid 44760180)
76. 3H]AL- 11. Mol. Cell. Endocrinol. 2009, 311, 77-86.
77. Grauer, A.; König, B. Peptidomimetics-a versatile route to biologically active compounds. Eur. J. Org. Chem. 2009, 2009, 5099-5111.
78. Mollica, A.; Paglialunga Paradisi, M.; Torino, D.; Spisani, S.; Lucente, G. Hybrid R/β-peptides: For-Met-Leu-Phe-OMe analogues containing geminally disubstituted β2,2- and β3,3-amino acids at the central position. Amino Acids 2006, 30, 453-459. (Pubitemid 43886906)
79. Schumann, F.; Müller, A.; Koksch, M.; Müller, G.; Sewald, N. Are β-amino acids γ-turn mimetics? Exploring a new design principle for bioactive cyclopeptides. J. Am. Chem. Soc. 2000, 122, 12009-12010.
80. Aguilar, M. I.; Purcell, A. W.; Devi, R.; Lew, R.; Rossjohn, J.; Smith, A. I.; Perlmutter, P. Beta-amino acid-containing hybrid peptides- new opportunities in peptidomimetics. Org. Biomol. Chem. 2007, 5, 2884-2890. (Pubitemid 47340677)
81. Chatterjee, J.; Gilon, C.; Hoffman, A.; Kessler, H. N-Methylation of peptides: A new perspective in medicinal chemistry. Acc. Chem. Res. 2008, 41, 1331-1342.
82. Rajeswaran, W. G.; Hocart, S. J.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity. J. Med. Chem. 2001, 44, 1416-1421. (Pubitemid 32852117)
83. Kiyoshi, I.; Yoshitaka, N.; Yuko, O.; Masahide, T.; Kanako, N.; Futoshi, M.; Takashi, I.; Tadashi, Y. Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition. J. Biol. Chem. 2006, 281, 33664-33676.
84. Tholander, F.; Muroya, A.; Roques, B. P.; Fournie-Zaluski, M. C.; Thunnissen, M. M.; Haeggstrom, J. Z. Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: Implications for M1 aminopeptidases and inhibitor design. Chem. Biol. 2008, 15, 920-929.
85. Ye, S.; Chai, S. Y.; Lew, R. A.; Ascher, D. B.; Morton, C. J.; Parker, M. W.; Albiston, A. L. Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase. Biochem. Cell Biol. 2008, 86, 251-261. (Pubitemid 351810525)
86. Sigel, H.; Martin, R. B. Coordinating properties of the amide bond. Stability and structure of metal ion complexes of peptides and related ligands. Chem. Rev. 1982, 82, 385-426.
87. Stadler, A.; Kappe, C. O. The effect of microwave irradiation on carbodiimide-mediated esterifications on solid support. Tetrahedron 2001, 57, 3915-3920. (Pubitemid 32382205)
88. Johansen, T. E.; Scholler, M. S.; Tolstoy, S.; Schwartz, T. W. Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors. FEBS Lett. 1990, 267, 289-294. (Pubitemid 20216711)
89. Le, M. T.; De Backer, J. P.; Hunyady, L.; Vanderheyden, P. M.; Vauquelin, G. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHOK1 cells. Eur. J. Pharmacol. 2005, 513, 35-45. (Pubitemid 40692244)
90. 125I]Ang IV binding and catalytic activity. Biochem. Pharmacol. 2004, 68, 885-892. (Pubitemid 39044516)
91. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.